Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review - 09/12/19
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Immunotherapy using programmed cell death 1 protein (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has been increasingly reported in a variety of nonmelanoma skin cancers (NMSCs).
Objective |
To analyze the evidence of PD-1 and PD-L1 inhibitors in the treatment of NMSC.
Methods |
A primary literature search was conducted with the PubMed, Cochrane Library, EMBASE, Web of Science, and CINAHL databases through October 28, 2018, to include studies on the use of PD-1 or PD-L1 inhibitors in patients for NMSC. Two reviewers independently performed study selection, data extraction, and critical appraisal.
Results |
This systematic review included 51 articles. The most robust evidence was in the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinomas, as supported by phase 1 and 2 clinical trials. Treatment of basal cell carcinoma, cutaneous sarcoma, sebaceous carcinoma, and malignant peripheral nerve sheath tumor also showed benefit with PD-1/PD-L1 inhibitors, but data are limited. There does not appear to be efficacy for PD-1/PD-L1 inhibitors in cutaneous lymphomas.
Limitations |
More investigation is needed to determine the efficacy, tumor responsiveness, and the safety profile of PD-1 and PD-L1 inhibitors in NMSC.
Conclusion |
PD-1 and PD-L1 inhibitors exhibit treatment efficacy in a variety of NMSCs.
Le texte complet de cet article est disponible en PDF.Key words : BCC, cutaneous lymphoma, MCC, NMSCs, nonmelanoma skin cancers, PD-1 inhibitors, PD-L1 inhibitors, sarcomas, SCC, sebaceous carcinoma
Abbreviations used : AE, BCC, CR, cSCC, CTLA-4, DP, FDA, ICOS, KS, LAG3, MCC, MPNST, NMSC, PD-1, PD-L1, PFS, PR, PRISMA, RECIST, SD, UPS
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?